Tetragenex Pharmaceuticals, Inc.
1 Maynard Drive
Suite 105
Park Ridge,
NJ 07656
United States - Map
Phone: 201-505-1300
Fax: 201-505-1501
Web Site: http://www.tetragenex.com
| Tetragenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceutical products to treat serious diseases. The companys principal product includes Nemifitide, an antidepressant compound, which is in late Phase II human clinical trials for the treatment of depression, anxiety, and other central nervous system disorders. It is also developing tetracycline molecules, which are in pre-clinical development stage for use in the treatment of certain types of cancer and antibiotic-resistant bacterial infections. The company was founded in 1989 and is headquartered in Englewood Cliffs, New Jersey. On August 9, 2009, Tetragenex Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Martin F. Schacker , 52
Chairman and Co-Chief Exec. Officer |
$
300.00K | N/A | Mr. David Abel , 66
Vice Chairman, Co-Chief Exec. Officer, Treasurer and Member of Compensation Committee |
$
110.00K | N/A | Mr. Neil Martucci , 37
Chief Financial Officer and Principal Accounting Officer |
$
100.00K | N/A | Mr. Robert P. Budetti , 67
Chief Operating Officer |
$
0 | N/A | Dr. Kenneth Cartwright M.B., CH.B., M.R.C.P., 74
Chief Scientific Officer, Sr. VP of Drug Devel. & Regulatory Affairs |
$
60.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
Profile
